Targeting Oral Cancer

This book provides research-oriented care providers with up-to-date information on the oral cancer patient population, the ways in which we are treating them, and the scientific approaches being pursued in order to improve survival and reduce treatment-related morbidity. The text is organized into three sections covering epidemiology and management, cancer development and biomarkers, and breaking developments and novel approaches for drug discovery. The first section includes discussion of the emerging role of HPV in oral cancer and explains the surgical, chemotherapy and radiation approaches to treatment. Aspects such as molecular progression, the role of cancer stem cells in tumor development, and the value of various biomarkers are then examined. The final section is devoted to the latest advances and covers, among other topics, current clinical trials, emerging drug targets, and targeting of the unfolded protein response and of mediators of coagulation.

Epidemiology and Management: Epidemiology.- Emerging Role of HPV.- Management of Oral Cancer. Development and Biomarkers: Molecular Progression and Signaling.- Stem Cells and Tumor Development.- Prognostic/Predictive Biomarkers.- EIF4e as Biomarker and Target. Breaking Developments and New Drug Discovery: Current Clinical Trials.- Emerging Drug Targets.- Targeting the UPR.- Targeting Meditators of Coagulation.- Resveratrol Pre-Sensitizing.- Academic High Throughput Drug Discovery.

Andrew M. Fribley graduated with a BS from Central Michigan University, Mt. Pleasant, MI and in 2005 gained his PhD from the University of Michigan, Ann Arbor, MI (Program in Oral Health Sciences, University of Michigan School of Dentistry). He then worked as a Post-Doctoral Research Fellow in the University of Michigan, School of Medicine, Department of Biological Chemistry and the Howard Hughes Medical Institute In 2010, Dr. Fribley was appointed Assistant Professor of Pediatrics at Wayne State University (Division of Hematology/Oncology), Detroit, MI. He is also an Associate in the Department of Otolaryngology at Wayne State University and a Scientific Member of the Karmanos Cancer Institute (Molecular Therapeutics Program). Dr. Fribley has received various awards, including the William J. Gies Award for the most outstanding manuscript published in the Journal of Dental Research (2003) and the Edward Hatton Award (First Prize, Senior Category) from the American Association of DentalResearch and the International Association of Dental Research (2004). Since 2012 he has been a member of the Fellowships Committee of the American Association of Dental Research. He has published original articles in a variety of leading peer-reviewed journals.